Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07182279 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
A Phase 1 study of Prostate Cancer (Adenocarcinoma), sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT07182279 is a Phase 1 study of Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 29 participants, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07182279, a Phase 1 study of Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Conditions Studied
Interventions
- DRUG Brachytherapy
Study Locations (1)
Texas
- Houston Methodist - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2026-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07182279
The ClinicalTrials.gov registry entry for NCT07182279 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (77% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which Brachytherapy is the first listed.
NCT07182279 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07182279 about?
NCT07182279 is a clinical study titled "Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer". This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled...
What is the current status of trial NCT07182279?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2025-08-01. Estimated completion is 2026-11-14.
What conditions does trial NCT07182279 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma).
What interventions are being tested in trial NCT07182279?
The interventions under investigation include: Brachytherapy (DRUG).
Who is sponsoring clinical trial NCT07182279?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07182279 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.